@article{13b4eaeed1914693858fcc4eac1581cb,
title = "Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone",
abstract = "Aims: Remote monitoring of pulmonary artery pressure has reduced heart failure (HF) hospitalizations in chronic HF as elevation of pulmonary artery pressure provides information that can guide treatment. The venous system is characterized by high capacitance, thus substantial increases in intravascular volume can occur before filling pressures increase. The inferior vena cava (IVC) is a highly compliant venous conduit and thus a candidate for early detection of change in intravascular volume. We aimed to compare IVC cross-sectional area using a novel sensor with cardiac filling pressures during experimental manipulation of volume status, vascular tone, and cardiac function. Methods and results: Experiments were conducted in sheep to manipulate volume status (colloid infusion), vascular tone (nitroglycerin infusion) and cardiac function (rapid cardiac pacing). A wireless implantable IVC sensor was validated ex-vivo and in-vivo, and then used to measure the cross-sectional area of the IVC. Right- and left-sided cardiac filling pressures were obtained via right heart catheterization. The IVC sensor provided highly accurate and precise measurements of cross-sectional area in ex-vivo and in-vivo validation. IVC area changes were more sensitive than the corresponding changes in cardiac filling pressures during colloid infusion (p < 0.001), vasodilatation (p < 0.001) and cardiac dysfunction induced by rapid pacing (p ≤ 0.02). Conclusions: Inferior vena cava area can be remotely and accurately measured in real time with a wireless implantable sensor. Changes in IVC area are more sensitive than corresponding changes in filling pressures following experimental volume loading and fluid redistribution. Additional research is warranted to understand if remote monitoring of the IVC may have advantages over pressure-based monitors in HF.",
keywords = "Animal, Heart failure, Inferior vena cava, Models, Venous pressure",
author = "Ivey-Miranda, {Juan B.} and Friedrich Wetterling and Robert Gaul and Stephen Sheridan and Asher, {Jennifer L.} and Rao, {Veena S.} and Christopher Maulion and Devin Mahoney and Alexandre Mebazaa and Gray, {Alastair P.} and Daniel Burkhoff and Cowie, {Martin R.} and Cox, {Zachary L.} and Javed Butler and Marat Fudim and Kenneth McDonald and Kevin Damman and Borlaug, {Barry A.} and Testani, {Jeffrey M.}",
note = "Funding Information: This study was funded by FIRE1. The sponsor participated in data generation, analysis of the raw signal data, and in the review and approval of the manuscript. Conflict of interest: J.B. declares that he serves as a consultant for Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, FIRE1, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, and Vifor. M.F. was supported by NHLBI K23HL151744 from the National Heart, Lung, and Blood Institute (NHLBI), the American Heart Association grant No 20IPA35310955, Mario Family Award, Duke Chair's Award, Translating Duke Health Award, Bayer and BTG Specialty Pharmaceuticals. He receives consulting fees from AxonTherapies, Bodyport, CVRx, Daxor, Edwards LifeSciences, NXT Biomedical, Zoll, Viscardia. J.M.T. reports grants and personal fees from 3ive labs, Boehringer Ingelheim, Reprieve medical, FIRE1, Sanofi, Sequana Medical, Merck, personal fees from Bayer, Bristol Myers Squibb, AstraZeneca, Novartis, Cardionomic, MagentaMed, W.L. Gore, Windtree Therapeutics, Lexicon pharmaceuticals, Regeneron, Edwards, BD, Precardia, grants from Otsuka, Abbott, outside the submitted work; In addition, J.M.T. has a patent Treatment of diuretic resistance US20200079846A1 issued to Yale and Corvidia Therapeutics Inc. and a patent Methods for measuring renalase WO2019133665A2 issued to Yale. All other authors have nothing to disclose. Funding Information: This study was funded by FIRE1. The sponsor participated in data generation, analysis of the raw signal data, and in the review and approval of the manuscript. Publisher Copyright: {\textcopyright} 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.",
year = "2022",
month = mar,
doi = "10.1002/ejhf.2395",
language = "English (US)",
volume = "24",
pages = "455--462",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",
}